News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Epocrates Inc. Cancels IPO
December 16, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Epocrates Inc., a San Mateo, Calif.-based provider of clinical information and support tools to healthcare professionals, has withdrawn plans for a $75 million IPO. It had planned to trade on the Nasdaq, with Citi serving as lead underwriter.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Immunology and inflammation
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar
October 23, 2026
·
1 min read
·
Annalee Armstrong
China
US explores China biotech restrictions, exempts licensing deals
October 23, 2026
·
3 min read
Deals
Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
October 23, 2026
·
2 min read
·
Tristan Manalac
IPO
Biotech notches 31 IPOs already this year, with 4 more joining queue
October 22, 2026
·
1 min read
·
Gabrielle Masson
